Neuland Laboratories Appoints New CEO & MD for CDMO Expansion
Filing Summary
Neuland Laboratories Ltd has announced the appointment of Saharsh Davuluri as the new Chief Executive Officer and Managing Director. This leadership change is effective immediately and aligns with the company’s strategy to expand its Contract Development and Manufacturing Organization (CDMO) operations. Neuland Laboratories, known for its expertise in complex Active Pharmaceutical Ingredients (APIs), has tripled its contract services revenue over the past three years. The company operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with plans for further expansion in commercial peptide capacity.
Neuland Laboratories Ltd has announced a leadership change with the appointment of Saharsh Davuluri as the new Chief Executive Officer and Managing Director. This change is effective immediately and is part of the company’s strategy to expand its Contract Development and Manufacturing Organization (CDMO) operations. Saharsh Davuluri has been with the company for over 18 years and succeeds Sucheth Davuluri, who will now serve as Executive Vice Chairman.
The company has reported significant growth in its contract services revenue, which has tripled over the past three years. Neuland Laboratories specializes in complex Active Pharmaceutical Ingredients (APIs) and has built a strong reputation for scaling up complex APIs and peptides. The company has secured numerous commercial manufacturing contracts with global innovator companies, reflecting increased demand for its process chemistry and reliable commercial supply capabilities.
Neuland Laboratories operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility. The company has an installed capacity of 1218 KL and holds more than 20 commercial contracts across APIs and intermediates. The company’s recent growth has been supported by its ability to accelerate development timelines through parallel development strategies while maintaining a strong regulatory track record across 18 US FDA inspections.
The company is embarking on an aggressive expansion phase, with plans to secure several more commercial New Chemical Entity (NCE) contracts, including peptides, over the next one to two years, pending customer approvals. Neuland Laboratories has committed to a four-phase expansion of commercial peptide capacity and is also doubling its process development capabilities.
Neuland Laboratories is listed on the NSE (NEULANDLAB) and BSE (524558) in India. The company has filed over 1000 Drug Master Files (DMFs) globally and offers more than 100 APIs across multiple therapeutic areas. Neuland Laboratories is a specialist API CDMO partner for big pharma and biotech, delivering process development and commercial supply services for complex molecules and New Chemical Entities.